Pembrolizumab Survival Benefit in Melanoma Sustained at 4 Years
Source: Targetdonc, June 2018
Pembrolizumab (Keytruda) induced a median overall survival (OS) of 32.7 months versus 15.9 months for ipilimumab (Yervoy) in patients with unresectable stage III-IV melanoma, according to 4-year survival results from the KEYNOTE-006 trial presented at the 2018 ASCO Annual Meeting.1
The HR for OS was 0.73 (95% CI, 0.61-0.89). The 4-year landmark OS was 41.7% for pembrolizumab compared with 34.1% for ipilimumab.